Kiora Pharmaceuticals, Inc. (KPRX)

NASDAQ: KPRX · IEX Real-Time Price · USD
7.70
+0.59 (8.30%)
Oct 4, 2022 1:10 PM EDT - Market open
8.30%
Market Cap 7.12M
Revenue (ttm) n/a
Net Income (ttm) -14.69M
Shares Out 919,078
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 418,615
Open 7.51
Previous Close 7.11
Day's Range 7.51 - 8.52
52-Week Range 4.88 - 87.60
Beta 0.27
Analysts Buy
Price Target 8.16 (+5.3%)
Earnings Date Nov 14, 2022

About KPRX

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid ... [Read more...]

Industry Biotechnology
CEO Stephen From
Employees 14
Stock Exchange NASDAQ
Ticker Symbol KPRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for KPRX stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 5.29% from the latest price.

Price Target
$8.16
(5.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists in...

Dallas, Texas--(Newsfile Corp. - September 28, 2022) - Stonegate Capital Partners will host a virtual investor event with ophthalmology experts to discuss Retinitis Pigmentosa (RP) and the pipeline of p...

6 days ago - Newsfile Corp

What Is Going on With Kiora Pharmaceuticals (KPRX) Stock Today?

Source: iQoncept / Shutterstock Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is in the news Tuesday as traders wonder what has the company's shares seeing wild movement. The big news affecting KPRX stock...

1 week ago - InvestorPlace

Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split

Salt Lake City, Utah--(Newsfile Corp. - September 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that its stockholders authorized a reverse stock split of th...

1 week ago - Newsfile Corp

Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance

Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mr...

3 weeks ago - Newsfile Corp

Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results

Salt Lake City, Utah--(Newsfile Corp. - August 12, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is reporting financial results for the three and six months ended ...

1 month ago - Newsfile Corp

Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics

Salt Lake City, Utah--(Newsfile Corp. - July 28, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has been granted a U.S. patent covering hydrogel-based sustained release pl...

2 months ago - Newsfile Corp

Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotm...

Salt Lake City, Utah--(Newsfile Corp. - July 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross p...

2 months ago - Newsfile Corp

Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering

Salt Lake City, Utah--(Newsfile Corp. - July 22, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross p...

2 months ago - Newsfile Corp

Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epi...

Salt Lake City, Utah--(Newsfile Corp. - July 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced enrolling the first patient as a part of a Phase 2 study ev...

2 months ago - Newsfile Corp

Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in ...

Salt Lake City, Utah--(Newsfile Corp. - June 27, 2022) -  Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") received approval to initiate a first-in-human clinical trial for KIO-301,...

3 months ago - Newsfile Corp

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Salt Lake City, Utah--(Newsfile Corp. - May 31, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced that on May 25, 2022, it received a letter from the Listing...

4 months ago - Newsfile Corp

Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and R...

Results support planned Phase 2 Trial to treat the Ocular Presentation of Rheumatoid Arthritis (OPRA)Salt Lake City, Utah--(Newsfile Corp. - April 25, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX),...

5 months ago - Newsfile Corp

Kiora Pharmaceuticals Reports 2021 Results and Provides Business Update

Salt Lake City, Utah--(Newsfile Corp. - April 15, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today reported its financial results for the quarter and year ended Decem...

5 months ago - Newsfile Corp

Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th

- To Participate in Ophthalmology Roundtable March 28, 10:00-11:00 AM ET -- To Provide On-Demand Corporate Presentation -Salt Lake City, Utah--(Newsfile Corp. - March 21, 2022) - Kiora Pharmaceuticals, ...

6 months ago - Newsfile Corp

Kiora Pharma Snags Orphan Drug Tag For Inherited Genetic Eye Disease Candidate

The FDA has granted Orphan Drug designation to Kiora Pharmaceuticals Inc's (NASDAQ: KPRX) KIO-301 for Retinitis Pigmentosa. Retinitis Pigmentosa is an inherited genetic eye disease that can lead to seve...

6 months ago - Benzinga

Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retin...

Salt Lake City, Utah--(Newsfile Corp. - March 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") has received Orphan Drug Designation from the U.S. Food and Drug Administ...

6 months ago - Newsfile Corp

Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference

Salt Lake City, Utah--(Newsfile Corp. - February 8, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that Brian M. Strem, Ph.D, President and CEO of Kiora, ...

7 months ago - Newsfile Corp

Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board

Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Di...

8 months ago - Newsfile Corp

Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference

Salt Lake City, Utah--(Newsfile Corp. - January 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian Str...

8 months ago - Newsfile Corp

Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors

Salt Lake City, Utah--(Newsfile Corp. - December 15, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced the appointment of David Hollander, MD, MBA, to its Board of ...

9 months ago - Newsfile Corp

Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients w...

Salt Lake City, Utah--(Newsfile Corp. - December 14, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced topline data from its vehicle-controlled, randomized safety ...

9 months ago - Newsfile Corp

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 and...

10 months ago - GlobeNewsWire

EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy

SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade...

10 months ago - GlobeNewsWire

EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bay...

EyeGate adds Bayon Therapeutics' portfolio of vision-restoring small molecules to its development pipeline EyeGate adds Bayon Therapeutics' portfolio of vision-restoring small molecules to its developme...

11 months ago - GlobeNewsWire

7 Best Penny Stocks to Buy on the Nasdaq for October

Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.

Other symbols: ECORPBTSSLDBUXINWIMI
1 year ago - InvestorPlace